Drug intelligence / Profile preview

mecopiprazole

Development stage: Unknown
Lead developer: Yantai Innoe Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

Mecopiprazole (YN001) is a novel small molecule multi-target modulator developed by Yantai Innoe Biotechnology for the treatment of Alzheimer's disease. It functions as a partial agonist at the 5-HT1A and dopamine D2 receptors and as an antagonist at the 5-HT2A receptor. This pharmacological profile is designed to address both the cognitive deficits and the behavioral and psychological symptoms of dementia (BPSD) by balancing serotonergic and dopaminergic neurotransmission. The drug is currently undergoing clinical evaluation in China, having completed initial Phase 1 safety and pharmacokinetic studies.

Other names: 美考哌唑

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on mecopiprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mecopiprazole.

Explore the full profile